RxDoctor Payments Data

Ramon Partida, MD

Interventional Cardiology · Larkspur, CANPI 1295994440

Payments from drug & device makers

$23,127in general payments, 2019–2025

Across 417 payments — averaging $55.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$8K
  • Abbott$7K
  • Medtronic$3K
  • Boston Scientific$3K
  • Abiomed$599
  • Heartflow, Inc.$514
  • plus $923 from 15 others

What the payments were for

  • Consulting fees$1,5006%
  • Speaking & faculty fees$1671%
  • Travel & lodging$5,44024%
  • Food & beverage$16,01869%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,127 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$322,916
Medicare patients
759
Services billed
2,839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$303,865
EntrestoSacubitril/Valsartan132$168,894
JardianceEmpagliflozin51$63,235
XareltoRivaroxaban49$60,538
BrilintaTicagrelor56$37,855
FarxigaDapagliflozin Propanediol22$37,266
Repatha SureclickEvolocumab18$22,910
Atorvastatin Calcium674$7,941
Metoprolol Succinate335$6,960
Pitavastatin Calcium23$4,233
Rosuvastatin Calcium172$4,187
VascepaIcosapent Ethyl11$3,639
Losartan Potassium289$3,534
Ranolazine ErRanolazine22$3,531
Ezetimibe135$3,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$62$75,12278 claims
Johnson & JohnsonXarelto$90$60,53849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Larkspur

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →